Medicare for All provides necessary incentives to increase innovation
Ibrahim Ribery Sep 24, 2020 Debunking the Medicare For All Innovation Dilemma https://ribery-ibrahim72.medium.com/debunking-the-medicare-for-all-innovation-dilemma-29d276383108
Arguing that innovation decreases due to decreased drug prices with M4A are absurd. Clearly, in the Medicare For All Bill, the price of a drug will be based on the societal value of the drug and the uniqueness of the drug. This system (also known as Value-Based Pricing) will not decrease the prices of new innovative medicines which a majority of small businesses create instead; it would not allow the creation of copycat, Me-Too, drugs by large pharmaceutical monopolies. Medicare For All solves the problems of the low competition in the production of the drugs as the government will brunt the cost of buying these drugs instead of the people. In a Value-Based System, there are two possibilities of the future of innovation At Best- Pharmaceutical company’s revenues will increase on the net because of the optimization of the prices of the drugs. In simple terms, small Pharma companies will not be affected because they already create new medicines that don’t subject them to the ruling of Value-Based Pricing. But now they don’t have Big Pharma creating a copycat and redirecting the market away. And it will change the incentives of Big Pharma because they will be forced to develop innovative drugs rather than the copycats. At worst- Only the revenues of Big Pharma will decrease because they have to shift away from their current strategy. While this may be bad right now, in the long term, it is essential to switch big companies’ incentives to create disruptive innovation. Big companies are larger, have more staff, and are self-funded meaning they can create more drugs in a quicker time and without being dependent on private investors to create life-saving diseases. Given these two possible scenarios innovating in a single-payer market is bound to increase with big pharma and small pharma. New innovation is very important in times like this and to prevent future diseases from becoming out of hand. Rather than innovating one step behind the disease under Medicare For All we will always be one step ahead